Recently the dual agonist of GLP-1RA/glucose-dependent insulinotropic polypeptide (GIP) (Tirzepatide) has been found to improve glycaemic control and reduce weight in patients with T2D and severe obesity [12] and in patients with severe obesity to reduce weight by up to 20% after a 72 week study period [13]. Here, GIP is linked to Obesity.